Burney Co. lifted its holdings in Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) by 297.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 507,044 shares of the biopharmaceutical company’s stock after purchasing an additional 379,501 shares during the period. Burney Co.’s holdings in Dynavax Technologies were worth $6,551,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in DVAX. Royce & Associates LP raised its holdings in Dynavax Technologies by 0.7% in the 2nd quarter. Royce & Associates LP now owns 442,257 shares of the biopharmaceutical company’s stock worth $5,714,000 after purchasing an additional 3,071 shares during the period. Stonepine Capital Management LLC purchased a new stake in Dynavax Technologies in the 1st quarter worth approximately $4,086,000. Credit Suisse AG raised its stake in Dynavax Technologies by 4.6% during the 1st quarter. Credit Suisse AG now owns 191,071 shares of the biopharmaceutical company’s stock worth $1,874,000 after acquiring an additional 8,366 shares during the period. Citigroup Inc. boosted its position in shares of Dynavax Technologies by 35.0% in the first quarter. Citigroup Inc. now owns 489,649 shares of the biopharmaceutical company’s stock worth $4,803,000 after purchasing an additional 126,979 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in shares of Dynavax Technologies in the first quarter worth $710,000. 99.13% of the stock is currently owned by institutional investors.
In other news, CMO Robert Janssen sold 5,015 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $15.03, for a total value of $75,375.45. Following the sale, the chief marketing officer now directly owns 49,925 shares in the company, valued at approximately $750,372.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CMO Robert Janssen sold 5,015 shares of Dynavax Technologies stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $15.03, for a total value of $75,375.45. Following the completion of the transaction, the chief marketing officer now owns 49,925 shares in the company, valued at approximately $750,372.75. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO David F. Novack sold 20,000 shares of the stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $15.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief operating officer now directly owns 3,187 shares in the company, valued at approximately $47,805. The disclosure for this sale can be found here. In the last ninety days, insiders sold 141,627 shares of company stock worth $2,092,122. 9.31% of the stock is currently owned by insiders.
Dynavax Technologies Price Performance
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on the stock. StockNews.com initiated coverage on shares of Dynavax Technologies in a report on Thursday, October 5th. They issued a “hold” rating for the company. HC Wainwright lifted their target price on Dynavax Technologies from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Finally, JMP Securities upped their price target on Dynavax Technologies from $25.00 to $27.00 and gave the stock a “market outperform” rating in a research note on Friday, November 3rd.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
- Five stocks we like better than Dynavax Technologies
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Left for dead, Tower Semiconductor is a phoenix rising
- Insider Trades May Not Tell You What You Think
- 3 specialty apparel makers ready to spring higher
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Boeing’s future sealed as China resumes order flow
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.